Sotigalimab Plus Nivolumab Shows Encouraging Activity in Anti–PD-1 Refractory Melanoma

Source: Onc Live, May 2022

The combination of sotigalimab (APX005M) and nivolumab (Opdivo) elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial (NCT03123783).

The doublet elicited an objective response rate (ORR) of 15.2% (95% CI, 6.2%-29.3%) among 33 evaluable patient; this included a partial response (PR) rate of 15.2% and a stable disease rate of 33.3%. Moreover, 51.5% of patients experienced disease progression. The duration of response from first documented PR to the end of the study ranged from 6 months to 25 months.

“These results are encouraging and warrant further investigation,” lead study author Sarah A. Weiss, MD, an assistant professor of medical oncology at Yale University School of Medicine, and colleagues, wrote in a poster shared during the 2021 SITC Annual Meeting. “In addition, sotigalimab’s activity and safety support investigation of combinations with other immune-oncology therapeutics in other clinical settings.”